103 related articles for article (PubMed ID: 30457249)
1. Expression of LMO2 in Prostate Carcinoma and Adjacent Prostatic Parenchyma.
Krušlin B; Vučić M; Mašić S; Kruljac I; Lež C; Ružić B; Spajić B; Ulamec M
Acta Clin Croat; 2018 Oct; 57(Suppl 1):56-60. PubMed ID: 30457249
[TBL] [Abstract][Full Text] [Related]
2. LIM domain only 2 over-expression in prostate stromal cells facilitates prostate cancer progression through paracrine of Interleukin-11.
Jiang CY; Yu JJ; Ruan Y; Wang XH; Zhao W; Wang XJ; Zhu YP; Gao Y; Hao KY; Chen L; Han BM; Xia SJ; Zhao FJ
Oncotarget; 2016 May; 7(18):26247-58. PubMed ID: 27028859
[TBL] [Abstract][Full Text] [Related]
3. [Regulation of E-cadherin promoter activity by LMO2 impact on the progression and metastasis of prostate cancer].
Peng X; Ye Z; Gao Y
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2013 Sep; 29(5):385-9. PubMed ID: 24386807
[TBL] [Abstract][Full Text] [Related]
4. [Effect of prostate peripheral zones stromal cells on the proliferation of prostate cells by overexpression of LMO2 gene].
Yu JJ; Wu YX; Xia SJ; Zhao FJ; Zhou GC
Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(2):91-4. PubMed ID: 26792688
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognostic role of syndecan-2 in prostate cancer.
Popović A; Demirović A; Spajić B; Stimac G; Kruslin B; Tomas D
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):78-82. PubMed ID: 19786981
[TBL] [Abstract][Full Text] [Related]
6. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels.
Miyashita K; Kitajima K; Goyama S; Kitamura T; Hara T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2310-2316. PubMed ID: 29278703
[TBL] [Abstract][Full Text] [Related]
8. LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype.
Patel JL; Pournazari P; Haggstrom SJ; Kosari F; Shabani-Rad MT; Natkunam Y; Mansoor A
Histopathology; 2014 Jan; 64(2):226-33. PubMed ID: 24330148
[TBL] [Abstract][Full Text] [Related]
9. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
10. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
[TBL] [Abstract][Full Text] [Related]
11. The impact of TRAIL on proliferation of secretory prostate cancer PC-3 cell and LMO2 gene expression.
Che Z; Li HW; Wang P; Jiang B; Li B; Zhao K; Wang SP; Gao H; Zhang MQ
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7172-7177. PubMed ID: 30468458
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy.
Kausik SJ; Blute ML; Sebo TJ; Leibovich BC; Bergstralh EJ; Slezak J; Zincke H
Cancer; 2002 Sep; 95(6):1215-9. PubMed ID: 12216087
[TBL] [Abstract][Full Text] [Related]
14. Residual prostatic tumour in the surgical bed following radical prostatectomy in organ-confined prostate cancer: possible prognostic significance.
Valotto C; Falconieri G; Pizzolitto S; Cerruto MA; Brondani G; De Gobbi A; Zattoni F
Arch Ital Urol Androl; 2011 Jun; 83(2):78-82. PubMed ID: 21826879
[TBL] [Abstract][Full Text] [Related]
15. LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.
Layer JH; Alford CE; McDonald WH; Davé UP
Mol Cell Biol; 2016 Feb; 36(3):488-506. PubMed ID: 26598604
[TBL] [Abstract][Full Text] [Related]
16. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
17. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
[TBL] [Abstract][Full Text] [Related]
18. [Expression and significance of HGAL and LMO2 in follicular lymphoma].
Zhang F; Luo D; Luo X; Chen Y; Xu J; Chen J; Zhuang H; Liu Y
Zhonghua Bing Li Xue Za Zhi; 2016 Feb; 45(2):83-5. PubMed ID: 26879427
[TBL] [Abstract][Full Text] [Related]
19. Biochemical Feature of LMO2 Interactome and LMO2 Function Prospect.
Wang W; Chen Y; Chang Y; Sun W
Med Sci Monit Basic Res; 2020 Jul; 26():e924421. PubMed ID: 32713935
[TBL] [Abstract][Full Text] [Related]
20. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
